ripretinib · Deciphera Pharms · NDA 213973
Qinlock
Earliest generic entry, as listed
6 Oct 2042
Blocked by patent: US 11779572. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 42 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11779572 | use U-3714 · sets the listed date | 6 Oct 2042 |
| US 11969414 | use U-3897 | 8 Feb 2041 |
| US 11185535 | drug product | 30 Dec 2040 |
| US 11395818 | drug product | 30 Dec 2040 |
| US 11576903 | drug product | 30 Dec 2040 |
| US 11612591 | drug product | 30 Dec 2040 |
| US 11793795 | drug product | 30 Dec 2040 |
| US 11801237 | drug product, use U-3219 | 30 Dec 2040 |
| US 11844788 | drug product | 30 Dec 2040 |
| US 11850240 | drug product | 30 Dec 2040 |
| US 11850241 | drug product | 30 Dec 2040 |
| US 11896585 | drug product | 30 Dec 2040 |
| US 11903933 | drug product | 30 Dec 2040 |
| US 11911370 | drug product | 30 Dec 2040 |
| US 11918564 | drug product | 30 Dec 2040 |
| US 11969415 | use U-3219 | 30 Dec 2040 |
| US 12023328 | use U-3957 | 30 Dec 2040 |
| US 12064422 | use U-3219 | 30 Dec 2040 |
| US 12213967 | drug product | 30 Dec 2040 |
| US 12213968 | drug product | 30 Dec 2040 |
| US 12226406 | drug product | 30 Dec 2040 |
| US 12318374 | drug product | 30 Dec 2040 |
| US 12708617 | use U-3219 | 30 Dec 2040 |
| US 10966966 | use U-3153 | 12 Aug 2040 |
| US 11266635 | use U-3330 | 12 Aug 2040 |
| US 11344536 | use U-3381 | 12 Aug 2040 |
| US 11426390 | use U-3416 | 12 Aug 2040 |
| US 11433056 | use U-3423 | 12 Aug 2040 |
| US 11529336 | use U-3382 | 12 Aug 2040 |
| US 11534432 | use U-3442 | 12 Aug 2040 |
| US 11576904 | use U-3537 | 12 Aug 2040 |
| US 11813251 | use U-3750 | 12 Aug 2040 |
| US 12023325 | use U-3960 | 12 Aug 2040 |
| US 12023326 | use U-3959 | 12 Aug 2040 |
| US 12023327 | use U-3958 | 12 Aug 2040 |
| US 12059410 | use U-3153 | 12 Aug 2040 |
| US 12059411 | use U-3971 | 12 Aug 2040 |
| US 12295944 | use U-4183 | 12 Aug 2040 |
| US 12318373 | use U-4191 | 12 Aug 2040 |
| US 8461179 | drug substance, drug product | 15 May 2034 |
| US RE48731 | use U-3219 | 7 Jun 2032 |
| US 8188113 | drug substance, drug product | 27 Jul 2030 |
Exclusivities · 1 unexpired
| ODE-298 | orphan drug (7 years) | 15 May 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213973 · 001 · RLD | tablet, oral | 50MG | 6 Oct 2042 |